key: cord-0975441-vf97d622
authors: Bessière, Pierre; Wasniewski, Marine; Picard-Meyer, Evelyne; Servat, Alexandre; Figueroa, Thomas; Foret-Lucas, Charlotte; Coggon, Amelia; Lesellier, Sandrine; Boué, Frank; Cebron, Nathan; Gausserès, Blandine; Trumel, Catherine; Foucras, Gilles; Salguero, Francisco J; Monchatre-Leroy, Elodie; Volmer, Romain
title: Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model
date: 2021-02-09
journal: bioRxiv
DOI: 10.1101/2021.02.09.430458
sha: 9027c6c2894c1c9dbd57e3d14890126e1680ac0c
doc_id: 975441
cord_uid: vf97d622

Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatments are beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. One Sentence Summary The timing of type I interferon treatment is a critical determinant of its efficacy against SARS-CoV-2 infection.

Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased 5 viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatments are beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. 10 One Sentence Summary:

The timing of type I interferon treatment is a critical determinant of its efficacy against SARS-CoV-2 infection.

Main Text: 15 Type I interferons (IFNs) are major antiviral cytokines and their finely tuned production is critical for host protection against viruses (1) . In vitro studies demonstrated that SARS-CoV-2 was very sensitive to the antiviral effects of type I IFN (2) (3) (4) . In addition, development of severe COVID-19 was shown to correlate with decreased type I IFNs production or impaired type I IFN signaling (5) (6) (7) (8) (9) . In agreement with these observations, recombinant type I IFNs are being tested 20 in a number of clinical trials to treat COVID-19 patients (10) (11) (12) . However, the design and interpretation of these clinical trials need to consider that the timing of type I IFN treatment may be critical for its efficacy and safety against SARS-CoV-2 (13, 14) . Indeed, studies in SARS-CoV and MERS-CoV infected mice demonstrated that type I IFN-treatment was beneficial when administered early, while it was deleterious when administered at later stages of infection (15, 25 16) . How the timing of type I IFN treatments modulate their clinical efficacy against SARS-CoV-2 is currently unknown and needs to be tested in an animal model.

To address this question, we designed a study that evaluated the prophylactic and therapeutic efficacy of intranasally administered recombinant universal IFN-α (rIFN) against SARS-CoV-2 infection in Syrian hamsters (Fig. 1A) . Hamsters intranasally infected with a high dose SARS- 30 CoV-2 develop clinical disease caused by lung pathology, which closely mirrors severe human COVID-19 (17, 18) . In a preliminary experiment, we observed a significant upregulation of the expression of the type I IFN stimulated gene (ISG) Mx2 in the nasal turbinates, lung and spleen of hamsters treated intranasally with rIFN, demonstrating that this molecule was active in hamsters (Fig. S1 ). Following challenge with 10 4 TCID 50 of SARS-CoV-2, no protection from 35 weight loss was observed in the IFN-late group, for which treatment was initiated at the onset of clinical signs, when infected animals started to significantly lose weight three days post-infection (Fig. 1B) . By contrast, we observed a significant protection from weight loss in the IFN-pre group (prophylactic treatment initiated 16 hours before infection) and in the IFN-early group (treatment initiated at one day post-infection) compared to the placebo group (Fig. 1B) . The 40 protection from weight loss in the IFN-pre and in the IFN-early groups was not associated with a reduction of viral excretion level or duration, as viral RNA levels measured by RT-qPCR from oropharyngeal swabs were similar in all groups (Fig. 1C ). In agreement with this observation, subgenomic viral RNA levels in the nasal turbinates were similar in all groups (Fig. S2 ). As SARS-CoV-2 respiratory disease is due to lower respiratory tract damage, we analyzed viral load in the lungs. We detected a reduction of pulmonary viral subgenomic RNA levels and infectious viral titers in all the IFN-treated groups at day 5 post-infection, compared to the placebo group, which reached statistical significance in the IFN-early group only ( Fig. 1 D&E) . 5 Evaluation of the respiratory tract from infected animals revealed a mild to moderate bronchointerstitial pneumonia at day 2 post-infection, progressing to moderate/severe with lung consolidation at day 5 and resolving at day 15 with only small lesioned areas remaining, as previously observed (18) . The lesions were characterized by infiltrates of macrophages and neutrophils, with fewer lymphocytes and plasma cells ( Fig. 2A & Fig. S3 ). A reduction of the 10 lung pathology scores was observed in the IFN-treated groups compared to the placebo group (Fig. 2B) . RNAScope in situ hybridization (ISH) was used to determine the localization of viral RNA in the lungs of infected animals. Viral RNA was observed in bronchial and bronchiolar epithelial cells and in regions of inflammatory infiltrates at day 2 post-infection (Fig. S3) . The viral RNA positive area diminished at day 5 and coincided with inflammatory infiltrates. 15 Quantification of viral RNA positive area revealed a slight non-statistically significant reduction of viral RNA in the IFN-pre and in the IFN-early groups at day 2 and 5 post-infection compared to the placebo group (Fig. 2C ). Mx1 is an ISG and its level of expression is a good indicator of the levels of type I and type III IFN produced locally (19) . Mx1 protein was upregulated in the lungs of infected hamsters, as detected by immunohistochemistry, and the percentage of Mx1 20 positive lung was equivalent in placebo and IFN-treated hamsters (Fig. 2D & Fig. S3 ). Finally, hematological analyses revealed a modest lymphocytopenia in SARS-CoV-2 infected hamsters, with no difference between the IFN-treated groups and the placebo group (Fig. S4) .

To explore the consequences of type I IFN administration on the immune response to SARS-CoV-2 infection, we analyzed the expression of immune markers gene expression from the lungs 25 of animals euthanized at day 2 and 5 post-infection. Compared to the non-infected animals, all the infected groups presented a significant upregulation of the ISGs Mx2 and ISG15 and of the C-X-C motif chemokine ligand 10 (CXCL10) messenger RNA (mRNA) expression at day 2 and 5 post-infection, with no difference between the placebo and the IFN-treated groups (Fig. 3A) . The mRNA expression levels of IFN-γ, and the interleukins (ILs) IL-10 and IL-6 were also 30 significantly upregulated in the infected animals at day 5 post-infection. Similar results were obtained for other immune markers analyzed by RT-qPCR in the lung (Fig. S5 ), nasal turbinates (Fig. S6) and spleen (Fig. S7) . We also measured the protein levels of chemokine and cytokines either in the lungs or plasma using a commercial enzyme-linked immunosorbent assay (ELISA) directed against hamster IL-6 or a custom-developed hamster multiplex assay. Compared to non- 35 infected animals, we detected an upregulation of CXCL10 and IL-10 protein levels in the lung of all infected groups, with no difference between the placebo and the IFN-treated groups (Fig. 3B) . We detected a reduction of lung IL-1β levels in IFN-treated groups compared to placebo. Interestingly, lung IL-6 protein level and plasmatic chemokine ligand 2 (CCL2) and tumor necrosis factor-α (TNF-α) protein levels were upregulated in the IFN-late group, compared to the 40 IFN-pre and IFN-early group (Fig. 3B&C) .

In this study, we assessed the in vivo prophylactic and therapeutic efficacy of type I IFN treatment against SARS-CoV-2 infection in the hamster model. Our study demonstrates that type I IFN treatment is beneficial when administered prophylactically or one day post-infection, confirming recent observations in hamsters (20) . Similar findings were obtained when mice were treated prophylactically or at 12 hours post-infection with type III interferon or with the synthetic viral RNA analog poly(I:C) (21, 22) . Altogether, these studies demonstrate that stimulation of the antiviral innate immune response before infection or at the very early phase of infection inhibits SARS-CoV-2 replication and pathogenesis, as expected given the high level of SARS-CoV-2 sensitivity to prophylactic type I and type III IFN treatment observed in cell culture (2) (3) (4) . 5 By contrasts, administration of type I IFN as soon as the animals exhibited the first clinical signs, corresponding to weight loss, three days post-infection, was not associated with any change in clinical signs compared to placebo treated hamsters. Therefore, this study does not support the use of intranasal type I IFN as a therapeutic in patients with COVID-19 symptoms.

In comparison to humans, virus replication and lung pathology progress much faster in hamsters, 10 which have a peak of virus replication in the lungs at day 2-3 and a peak in clinical signs at day 6-7 (17) . Treatment at day 3 post-infection thus corresponds to a "late" time point for treatment initiation in hamsters. We detected an upregulation of IL-6, CCL2 and TNF-α protein levels in the IFN-late group, compared to the IFN-pre and IFN-early groups. However, this did not result in enhanced pathology compared to the placebo group. Our results therefore indicate that type I 15 IFN treatments at late time-points are unlikely to be associated with deleterious immunopathology exacerbation mechanisms, which were observed in SARS-CoV-1 and MERS virus infected mice and feared in SARS-CoV-2-infected humans (13, 15, 16) . A contribution of type I IFNs to SARS-CoV-2 lung pathology has been suggested from work in IFNAR knockout mice transduced with adenovirus expressing human ACE2 and in STAT2 knockout hamsters 20 (21, 23, 24). However, heightened viral loads were also observed in IFNAR knockout mice and STAT2 knockout hamsters, illustrating the fact that type I IFNs can have beneficial and deleterious effects most likely depending on the stage of SARS-CoV-2 infection (21, 24) . SARS-CoV-2 expresses a broad array of type I IFN signaling antagonists that likely account for the low sensitivity observed in post-infection type I IFN treatments in cell culture (Fig. S8) , and for the 25 lack of beneficial effects observed in this study when type I IFN treatment was initiated at the onset of symptoms three days post-infection (4, 25, 26) .

Even though SARS-CoV-2 expresses a broad array of type I IFN signaling antagonists, we detected a significant upregulation of ISGs expression in the respiratory tract of SARS-CoV-2 infected hamsters, similarly to what has been described in COVID-19 patients (27) . Interestingly, 30 ISGs expression in the respiratory tract was not further increased by IFN treatments, as previously observed in MERS-CoV infected mice treated with IFN-beta at 2 days post-infection (16) . This result suggests that ISGs levels had reached their maximal in response to virusinduced endogenous type I and type III IFNs production and could not be further augmented following exogenous type I IFN administration. 35 Our study demonstrates that the timing of the type I IFN treatment is critical for its efficacy in a preclinical model of severe SARS-CoV-2 infection. Results from the SOLIDARITY clinical trial showed no benefit of subcutaneous interferon-β-1a injection, while a phase-two clinical trial provided evidence of some benefits of inhaled interferon-β-1a in COVID-19 patients (12, 28) . The route of type I IFN administration was not the sole difference between these trials, as the 40 patients treated in the SOLIDARITY trial were on average at a more severe stage of the disease. Our findings support the hypothesis that type I IFN treatments may only be beneficial in patients with mild symptoms at the early stages of the disease, while they are likely to provide no benefit in COVID-19 patients requiring hospitalization (29) . 

Type I interferons in infectious disease

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

Antiviral activities of type I interferons to SARS-CoV-2 infection

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

Impaired type I interferon activity and inflammatory responses in severe 20 COVID-19 patients

COVID Clinicians

Amsterdam UMC Covid-19 Biobank, COVID Human Genetic Effort

Amsterdam UMC Covid-19 Biobank

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

Genetic mechanisms of critical illness in Covid-19

Type 1 interferons as a potential treatment against COVID-19

The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19

Inhaled Interferon Beta COVID-19 Study Group, Safety and efficacy of inhaled 5 nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Animal models for COVID-19

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Induction of MxA Gene Expression by Influenza A Virus Requires Type I or Type III Interferon Signaling

Leveraging the antiviral type-I interferon system as a first line defense against SARS-CoV-2 pathogenicity

A mouseadapted model of SARS-CoV-2 to test COVID-19 countermeasures

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

Activation and evasion of type I interferon responses by SARS-CoV-2

Evasion of Type I Interferon by SARS-CoV-2

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Nebulised interferon beta-1a for patients with COVID-19

Dosedependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever

Differential Innate Immune Responses Elicited by Nipah Virus and 5

Cedar Virus Correlate with Disparate In Vivo Pathogenesis in Hamsters

Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)

Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters

STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids

) for granting access to the SARS-CoV-2 UCN1 strain and Daniel Gonzalez-Dunia for proofreading the manuscript. We thank Vanessa Bastid, Mélanie Badré-Biarnais

Funding: this work was funded by a grant from the Agence Nationale de la Recherche (ANR-20-COV5-0004)

Tables S1References (30) (31) (32) (33) (34) (35) (36) (37) (38)